SK Biopharmaceuticals has struck its first-ever settlement with a generic drug manufacturer seeking to produce a copycat version of its epilepsy treatment Xcopri (cenobamate). The agreement is with India’s MSN Laboratories, which
More
Artificial intelligence in mergers and acquisitions is no longer simply a productivity tool but a core component of how deals are structured and executed. The shift extends well beyond faster document review,
More
California’s Department of Housing and Community Development has adopted its final Loan Portfolio Restructuring Guidelines, effective June 9, 2026, reshaping how affordable housing developers can refinance state loans. The Guidelines were designed
More
Roberts recently penned a lengthy tribute to William Howard Taft, one that observers say reflects as much on Roberts’ own judicial record as on Taft’s historical contributions. Taft remains a unique figure
More
The Department of Justice finds itself in an unusual position, insisting that no one disputes the meaning of a term that appears to be disputed by virtually everyone involved. The Comey case
More
The FTSE 100 reversed early losses to close in positive territory on Wednesday after the US Treasury announced plans to significantly increase buybacks of longer-dated bonds. The blue-chip index ended the session
More
The United States government’s total debt has crossed a historic threshold, reaching $40.05 trillion as of Tuesday, according to the Treasury Department. The milestone arrives four and a half years after the
More
Ithaca Energy and Oxford Nanopore Technologies delivered standout performances among FTSE 250 constituents during a notably positive session for mid-cap stocks. Ithaca Energy, the North Sea-focused oil and gas producer, has been
More
Heavy overnight rain is threatening to drench the Knavesmire at York, with torrential thunderstorms forecast ahead of day two of the Ebor Festival. The going had already shifted to good, good-to-soft in
More
Regeneron Pharmaceuticals (REGN) has secured a landmark FDA approval for its monoclonal antibody garetosmab, now commercially known as Pasatru, after more than ten years in development. The drug becomes the second FDA-cleared
More